Who are local dexmedetomidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Catapresan TTS 2, Nebulized lidocaine and dexmedetomidine, Venlafaxine XR + Mirtazapine, oxymetazoline-fluticasone propionate, Norepinephrine (Levophed), Brimonidine/Timolol mixed combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/local-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

local dexmedetomidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

local dexmedetomidine (local dexmedetomidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesiology.

phase 3 Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

local dexmedetomidine (local dexmedetomidine) — The University of Hong Kong. Local dexmedetomidine acts as an alpha-2 adrenergic receptor agonist to induce sedation and analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
local dexmedetomidine TARGET	local dexmedetomidine	The University of Hong Kong	phase 3	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Catapresan TTS 2	Catapresan TTS 2	Heart Care Foundation	marketed	Central alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Nebulized lidocaine and dexmedetomidine	Nebulized lidocaine and dexmedetomidine	Ain Shams University	marketed	Local anesthetic and sedative-analgesic combination	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
oxymetazoline-fluticasone propionate	oxymetazoline-fluticasone propionate	Brian J Lipworth	marketed	Nasal decongestant/corticosteroid combination	Alpha-2 adrenergic receptor; glucocorticoid receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Brimonidine/Timolol mixed combination	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

Allergan · 3 drugs in this class
Eye & ENT Hospital of Fudan University · 2 drugs in this class
National Cancer Institute, Egypt · 2 drugs in this class
The University of Hong Kong · 2 drugs in this class
Sindh Institute of Urology and Transplantation · 2 drugs in this class
Fayoum University Hospital · 1 drug in this class
First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). local dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/local-dexmedetomidine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing